Pregabalin Capsule
Product Images NDC 68788-7520

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 68788-7520). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pregabalin Capsules 25mg (cv) (Pregabalin Caps 25mg 30ct)

Pregabalin Capsules 25mg (cv) (Pregabalin Caps 25mg 30ct)
This is a description of Pregabalin capsules, which come in 25mg strength and are a generic version of Lyrica. The label warns that it is illegal to transfer this medication to others. Each capsule contains the active ingredient pregabalin. The manufacturer is ScieGen Pharmaceuticals, and the batch number, package size, expiration date, and product number are also listed. There are also some unreadable characters in the text.*
FDA Label Image

Figure 1 (Pregabalin Fig01)

Figure 1 (Pregabalin Fig01)
FDA Label Image

Figure 2 (Pregabalin Fig02)

Figure 2 (Pregabalin Fig02)
FDA Label Image

Figure 3 (Pregabalin Fig03)

Figure 3 (Pregabalin Fig03)
FDA Label Image

Figure 4 (Pregabalin Fig04)

Figure 4 (Pregabalin Fig04)
FDA Label Image

Figure 5 (Pregabalin Fig05)

Figure 5 (Pregabalin Fig05)
FDA Label Image

Figure 6 (Pregabalin Fig06)

Figure 6 (Pregabalin Fig06)
This text seems to be a table of a study or studies concerning the effects of different doses of some medicine compared to a placebo. The table shows the results of at least three different studies (E1, E3, and S5) for which 150mg, 300mg, and 600mg/day of the medicine were administered, as well as the effects of the placebo. The text suggests that the effects of the medicine were statistically significant compared to the placebo, but there is not enough information to say what the medicine was, what it was used for, or what the effects were.*
FDA Label Image

Figure 7 (Pregabalin Fig07)

Figure 7 (Pregabalin Fig07)
FDA Label Image

Figure 9 (Pregabalin Fig08)

Figure 9 (Pregabalin Fig08)
FDA Label Image

Figure 10 (Pregabalin Fig09)

Figure 10 (Pregabalin Fig09)
This appears to be a table that shows the percentages of subjects without LTR (unclear what this refers to) for a treatment called "Progabain" and a placebo over a period of 120 days (from day 0 to day 120). The percentage varies from 0% to 100% for both groups.*
FDA Label Image

Figure 11 (Pregabalin Fig10)

Figure 11 (Pregabalin Fig10)
FDA Label Image

Figure 12 (Pregabalin Fig11)

Figure 12 (Pregabalin Fig11)
Percent of subjects improved over a certain period of time is being reported in the provided text. The extent of improvement from Bassine to Week 16 is also mentioned, which is 80%. The rest of the characters don't form readable text.*
FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

Cockcroft And Gault Equation (Pregabalin Formula)
This appears to be a formula for calculating the estimated creatinine clearance rate (CLCT) for patients based on their age, weight, and serum creatinine levels. The formula is different for female patients, as the result is multiplied by 0.85. However, the presence of the string "mmmmmmmmm e e" instead of a specific value suggests that there may be an error in the output.*
FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.